AFT lifts profit guidance after weak start

Hikma Pharmaceutical’s first sale of Maxigesic IV in the US delivers boost for AFT Pharmaceuticals  AFT Pharmaceuticals – the owner of the Maxigesic ibuprofen/paracetamol combination drug – has raised its operating profit guidance to $25m after a deal in the US triggered a new licensing fee.     AFT said the US licensee of Maxigesic IV,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy in limbo as 8CPA deadline looms
Next Butler urged to revisit remote dispensing